【目的】探讨强力枇杷露对慢性阻塞性肺疾病急性加重期（AECOPD）患者的临床疗效及肺功能和白细胞介素6（IL-6）、 C反应蛋白（CRP）、降钙素原（PCT）水平的影响。【方法】将80例痰热阻肺型AECOPD患者随机分为观察组和对照组，每组各 40例。对照组患者给予西医常规治疗，观察组患者在对照组的基础上给予强力枇杷露治疗，疗程为5 d。观察2组患者治疗 前后中医证候（咳嗽、咳痰、气短和喘息）评分、肺功能指标[第1秒最大呼气容积（FEV1）及其与用力肺活量（FVC）的比值 （FEV1/FVC）]、血气指标[动脉血氧分压（PaO2）、血氧饱和度（SaO2）和动脉二氧化碳分压（PaCO2）]及炎症因子IL-6、CRP、 PCT水平的变化情况，并评价2组患者的临床疗效和安全性。【结果】（1）疗效方面，治疗5 d后，观察组的总有效率为95.00% （38/40），对照组为77.50%（31/40），组间比较（χ2检验），观察组的疗效明显优于对照组（P＜0.05）。（2）中医证候评分方面，治 疗后，2组患者的咳嗽、咳痰、气短、喘息等中医证候评分均较治疗前降低（P＜0.05），且观察组的降低幅度均明显优于对 照组（P＜0.05）。（3）肺功能方面，治疗后，2组患者的FEV1/FVC、FEV1等肺功能指标均较治疗前改善（P＜0.05），且观察组 的改善幅度均明显优于对照组（P＜0.05）。（4）血气指标方面，治疗后，2组患者的PaO2、SaO2 水平均较治疗前升高（P＜ 0.05），PaCO2水平均较治疗前降低（P＜0.05），且观察组对PaO2、SaO2水平的升高幅度及对PaCO2水平的降低幅度均明显优于 对照组（P＜0.05）。（5）炎症因子方面，治疗后，2组患者血清IL-6、CRP、PCT水平均较治疗前降低（P＜0.05），且观察组的 降低幅度均明显优于对照组（P＜0.05）。（6）安全性方面，观察组的不良反应发生率为10.00%（4/40），对照组为7.50%（3/40）， 组间比较，差异无统计学意义（P＞0.05）。【结论】强力枇杷露治疗痰热阻肺型AECOPD患者疗效显著，能有效改善患者临床 症状，调节患者肺功能和血气指标，抑制炎症反应，且具有较高的安全性。

Objective To investigate the clinical efficacy of Qiangli Pipa Syrup for the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease（AECOPD），and to observe its effects on pulmonary function and interleukin 6（IL-6）， C-reactive protein（CRP）and procalcitonin（PCT）levels in the patients. Methods Eighty patients with AECOPD of phlegm-heat obstructing the lung syndrome were randomly divided into the observation group and the control group， with 40 patients in each group. Patients in the control group were treated with conventional western medicine，and patients in the observation group were treated with Qiangli Pipa Syrup on the basis of treatment for the control group. Both groups were treated for 5 days. The two groups were observed in the changes of traditional Chinese medicine（TCM）syndrome scores（including cough，expectoration， 广州中医药大学学报 Journal of Guangzhou University of Traditional Chinese Medicine 2024年3月第41卷第3期 March 2024，Vol. 41，No. 3 569 shortness of breath，and wheezing），pulmonary function parameters [the forced expiratory volume in one second （FEV1）and the ratio of FEV1 to the forced vital capacity（FVC）（FEV1/FVC）]， blood gas indicators [arterial partial pressure of oxygen（PaO2），blood oxygen saturation（SaO2）and arterial partial pressure of carbon dioxide （PaCO2）] and the levels of the inflammatory factors of IL- 6， CRP， and PCT before and after treatment. Moreover， the clinical efficacy and safety of the patients in the two groups were evaluated. Results（1）After 5 days of treatment，the total effective rate of the observation group was 95.00%（38/40），and that of the control group was 77.50%（31/40）. The intergroup comparison（tested by chi-square test）showed that the therapeutic effect of the observation group was significantly superior to that of the control group （P＜0.05）.（2）After treatment， the TCM syndrome scores of cough， expectoration， shortness of breath， and wheezing in the two groups were reduced compared with those before treatment（P＜0.05），and the reduction in the observation group was significantly superior to that in the control group（P＜0.05）.（3）After treatment， the pulmonary function parameters of FEV1/FVC and FEV1 in the two groups were improved compared with those before treatment（P＜ 0.05），and the improvement in the observation group was significantly superior to that in the control group（P＜ 0.05）.（4）After treatment， the blood gas indicators of PaO2 and SaO2 levels in the two groups were increased compared with those before treatment（P＜0.05），and the PaCO2 level was decreased compared with that before treatment（P＜0.05）. The increase of PaO2 and SaO2 levels and the decrease of PaCO2 level in the observation group were significantly superior to those in the control group（P＜0.05）.（5）After treatment，the serum levels of inflammatory factors of IL-6， CRP， and PCT in the two groups were lower than those before treatment（P＜ 0.05），and the reduction in the observation group was significantly superior to that in the control group（P＜0.05）. （6）The incidence of adverse reactions in the observation group was 10.00%（4/40），while that in the control group was 7.50%（3/40）. There was no significant difference between the two groups（P＞0.05）. Conclusion Qiangli Pipa Syrup exerts certain effect in treating patients with AECOPD of phlegm-heat obstructing the lung syndrome，which can effectively relieve the clinical symptoms， improve the pulmonary function and blood gas indicators， and inhibit inflammatory response of the patients，with high safety profile.

R563.3；R259.63

安徽省重点研究与开发计划（第一批）立项项目（编号：202104j07020052）；亳州市重点研发计划（自筹经费）项目（编号：bzzc2021019）